Anti-Pseudomonas Antibiotics

Definition and Classification

Anti-pseudomonal antibiotics specifically target Pseudomonas aeruginosa, a gram-negative bacterium known for its intrinsic resistance to many conventional antibiotics 2
These specialized antibiotics are critical for treating Pseudomonas infections, which can range from colonization to chronic infection 1
They are particularly important for managing difficult-to-treat resistant P. aeruginosa, defined as isolates non-susceptible to standard first-line agents 2

Polymyxins, such as colistin, are commonly used at doses of 1-3 million units twice daily, with minimal development of resistance reported 1, 3
Inhaled formulations, including colistin and tobramycin, deliver high concentrations directly to the site of infection while minimizing systemic toxicity 4

Newer beta-lactam/beta-lactamase inhibitor combinations, such as ceftolozane/tazobactam and ceftazidime/avibactam, are first-line options for difficult-to-treat resistant P. aeruginosa 2
Imipenem/cilastatin-relebactam and cefiderocol are potential alternatives for treating difficult-to-treat resistant P. aeruginosa 2

Combination therapy may be considered in specific cases, particularly with fosfomycin as a companion agent 2

Nebulized antibiotics should be administered using a compressor with appropriate flow rate and a nebulizer that produces aerosol particles of 2-5 mm diameter 3
Patients should be instructed on proper cleaning and drying of nebulizers to prevent contamination 3
Bronchospasm is the major side effect of nebulized antibiotic therapy; patients should be tested for bronchial constriction when starting a new inhaled antibiotic 3

Early aggressive treatment of initial P. aeruginosa colonization can delay the onset of chronic infection 3
For chronic P. aeruginosa infection, regular maintenance treatment is recommended with either intravenous antibiotics or continuous nebulized antibiotics throughout the year 3
Any acute exacerbation should be treated promptly with appropriate antibiotics 3

Monitoring for resistance development is essential, particularly with long-term therapy 4
For patients with difficult-to-treat resistant P. aeruginosa, novel beta-lactam agents are preferred over colistin-based therapy due to colistin's narrow therapeutic window and high nephrotoxicity risk 2
Caution is needed when patients receive intravenous aminoglycosides in addition to high-dose aerosolized antibiotics due to potential cumulative toxicity 3